The valve, designed with a new-look sealing cuff for limiting paravalvular regurgitation, gained FDA approval in January 2023. 

The news comes as more and more medications, including Lilly's own tirzepatide, are being used to treat both obesity and diabetes. 

Private equity is becoming more and more influential in many healthcare specialties, including cardiology. This has prompted increased speculation about the impact such investments may have on patient outcomes.

Early research suggests initiating therapy with senescence-inhibiting drugs could limit the risk of these side effects. 

“We identified a problem in cardiology,” one cardiologist explained. “Heart imaging has made remarkable progress in recent decades, but the electrics of the heart have eluded us."

Asian patients are rarely represented in large TAVR trials, the authors wrote, so they focused on nearly 1,200 patients from South Korea to provide a fresh perspective. 

A hybrid approach may increase the risk of certain adverse events, according to a new meta-analysis focused on long-term outcomes. 

Abbott's HeartMate 3 LVAD is the only FDA-approved device of its kind currently available in the United States. Should reports of adverse events worry cardiologists? Or are they to be expected when treating such a vulnerable patient population?